Display options
Share it on

Oncotarget. 2017 Dec 17;9(2):1505-1523. doi: 10.18632/oncotarget.23351. eCollection 2018 Jan 05.

Developmental and light regulation of tumor suppressor protein PP2A in the retina.

Oncotarget

Ammaji Rajala, Yuhong Wang, Steven F Abcouwer, Thomas W Gardner, Raju V S Rajala

Affiliations

  1. Department of Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
  2. Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
  3. Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  4. W.K. Kellogg Eye Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  5. Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
  6. Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.

PMID: 29416710 PMCID: PMC5788578 DOI: 10.18632/oncotarget.23351

Abstract

Protein phosphatases are a group of universal enzymes that are responsible for the dephosphorylation of various proteins and enzymes in cells. Cellular signal transduction events are largely governed by the phosphorylation of key proteins. The length of cellular response depends on the activation of protein phosphatase that dephosphorylates the phosphate groups to halt a biological response, and fine-tune the defined cellular outcome. Dysregulation of these phosphatase(s) results in various disease phenotypes. The retina is a post-mitotic tissue, and oncogenic tyrosine and serine/ threonine kinase activities are important for retinal neuron survival. Aberrant activation of protein phosphatase(s) may have a negative effect on retinal neurons. In the current study, we characterized tumor suppressor protein phosphatase 2 (PP2A), a major serine/ threonine kinase with a broad substrate specificity. Our data suggest that PP2A is developmentally regulated in the retina, localized predominantly in the inner retina, and expressed in photoreceptor inner segments. Our findings indicate that PKCĪ± and mTOR may serve as PP2A substrates. We found that light regulates PP2A activity. Our studies also suggest that rhodopsin regulates PP2A and its substrate(s) dephosphorylation. PP2A substrate phosphorylation is increased in mice lacking the A-subunit of PP2A. However, there is no accompanying effect on retina structure and function. Together, our findings suggest that controlling the activity of PP2A in the retina may be neuroprotective.

Keywords: Gerotarget; anti-oncogene; mechanistic target of rapamycin; protein kinase C; protein phosphatase-2A; retina

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no competing financial interests.

References

  1. Am J Pathol. 2003 Feb;162(2):479-89 - PubMed
  2. Nat Rev Mol Cell Biol. 2012 Apr 04;13(5):283-96 - PubMed
  3. Mol Cell Biol. 2011 Sep;31(18):3832-44 - PubMed
  4. Eur J Biochem. 2002 Jan;269(2):546-52 - PubMed
  5. J Clin Invest. 2015 Apr;125(4):1446-58 - PubMed
  6. Oncogene. 2001 Apr 5;20(15):1892-9 - PubMed
  7. Sci Rep. 2016 Nov 24;6:37727 - PubMed
  8. J Biol Chem. 2010 Mar 19;285(12):8894-904 - PubMed
  9. J Neurosci. 2007 Jan 3;27(1):203-11 - PubMed
  10. Cell. 1995 Jan 27;80(2):225-36 - PubMed
  11. Physiol Rev. 2008 Oct;88(4):1341-78 - PubMed
  12. FEBS Lett. 2007 Jul 24;581(18):3494-8 - PubMed
  13. J Invest Dermatol. 2008 Apr;128(4):980-7 - PubMed
  14. Proc Natl Acad Sci U S A. 1924 Jul;10(7):329-33 - PubMed
  15. Biochem J. 2003 Mar 1;370(Pt 2):361-71 - PubMed
  16. Cancer Res. 2005 Sep 15;65(18):8183-92 - PubMed
  17. Biochem J. 2001 Feb 1;353(Pt 3):417-39 - PubMed
  18. EMBO J. 2005 Mar 23;24(6):1211-21 - PubMed
  19. Biochemistry. 2002 Nov 19;41(46):13526-38 - PubMed
  20. J Biol Chem. 1999 Mar 5;274(10):6085-90 - PubMed
  21. Mol Cell Biol. 1997 Mar;17(3):1692-701 - PubMed
  22. PLoS One. 2011;6(11):e27424 - PubMed
  23. Enzyme Res. 2011;2011:329098 - PubMed
  24. Invest Ophthalmol Vis Sci. 2016 Mar;57(3):1418-30 - PubMed
  25. Sci Signal. 2014 Jul 22;7(335):ra68 - PubMed
  26. Oncogene. 2001 Jan 4;20(1):10-5 - PubMed
  27. J Hered. 1965 Jan-Feb;56:23-9 - PubMed
  28. Leukemia. 2004 Mar;18(3):505-12 - PubMed
  29. Nat Genet. 2003 Oct;35(2):158-64 - PubMed
  30. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6097-102 - PubMed
  31. Invest Ophthalmol Vis Sci. 1992 Nov;33(12):3367-77 - PubMed
  32. Diabetes. 2014 Sep;63(9):3077-90 - PubMed
  33. Circ Res. 2010 Apr 30;106(8):1319-31 - PubMed
  34. Invest Ophthalmol Vis Sci. 2010 Nov;51(11):6051-8 - PubMed
  35. Exp Eye Res. 1991 Jul;53(1):101-5 - PubMed
  36. Cell. 2006 Oct 20;127(2):341-53 - PubMed
  37. Cytogenet Cell Genet. 1993;63(1):35-41 - PubMed
  38. Science. 1992 Aug 28;257(5074):1261-4 - PubMed
  39. J Biol Chem. 1994 Mar 18;269(11):7957-62 - PubMed
  40. Nat Genet. 1998 Dec;20(4):344-51 - PubMed
  41. Nat Genet. 2001 Dec;29(4):447-52 - PubMed
  42. Am J Physiol Regul Integr Comp Physiol. 2010 Dec;299(6):R1610-7 - PubMed
  43. J Neurosci. 2003 Apr 15;23 (8):3124-9 - PubMed
  44. Nature. 1990 Oct 18;347(6294):677-80 - PubMed
  45. Mol Cancer Ther. 2008 Sep;7(9):2609-20 - PubMed
  46. Mol Cell Biol. 1998 Jan;18(1):250-9 - PubMed

Publication Types

Grant support